Sera from Patients with Malignant Pleural Mesothelioma Tested Positive for IgG Antibodies against SV40 Large T Antigen: The Viral Oncoprotein.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
08
2021
revised:
27
01
2022
accepted:
11
06
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
Malignant pleural mesothelioma (MPM), a fatal tumor, is mainly linked to the asbestos exposure. It has been reported that together with the inhalation of asbestos fibers, other factors are involved in the MPM onset, including simian virus 40 (SV40). SV40, a polyomavirus with oncogenic potential, induces (i) in vitro the mesenchymal cell transformation, whereas (ii) in vivo the MPM onset in experimental animals. The association between MPM and SV40 in humans remains to be elucidated. Sera (n = 415) from MPM-affected patients (MPM cohort 1; n = 152) and healthy subjects (HSs, n = 263) were investigated for their immunoglobulin G (IgG) against simian virus 40 large tumor antigen (Tag), which is the transforming protein. Sera were investigated with an indirect enzyme-linked immunosorbent assay (ELISA) using two synthetic peptides from SV40 Tag protein. SV40 Tag protein was evaluated by immunohistochemical (IHC) staining on MPM samples (MPM cohort 2; n = 20). Formalin-fixed and paraffin-embedded (FFPE) samples were obtained from MPM patients unrelated to MPM serum donors. The proportion of sera, from MPM patients, showing antibodies against SV40 Tag (34%) was significantly higher compared to HSs (20%) (odds ratio 2.049, CI 95% 1.32-3.224;
Identifiants
pubmed: 35874636
doi: 10.1155/2022/7249912
pmc: PMC9307391
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7249912Informations de copyright
Copyright © 2022 Elisa Mazzoni et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest for this work.
Références
Front Oncol. 2018 Apr 03;8:91
pubmed: 29666782
Ann Transl Med. 2017 Jun;5(11):238
pubmed: 28706906
Int J Cancer. 2007 Jun 1;120(11):2459-65
pubmed: 17315193
J Thorac Dis. 2018 Jan;10(Suppl 2):S253-S261
pubmed: 29507793
J Infect. 2019 Jun;78(6):476-483
pubmed: 30965068
Oncol Rep. 2002 May-Jun;9(3):631-4
pubmed: 11956641
Expert Rev Mol Med. 2012 May 24;14:e12
pubmed: 22622048
Lancet Oncol. 2013 Jun;14(7):576-8
pubmed: 23725699
Cancer Res. 2005 Apr 1;65(7):2602-9
pubmed: 15805256
IARC Monogr Eval Carcinog Risks Hum. 2014;104:9-350
pubmed: 26173303
Eur Respir Rev. 2015 Mar;24(135):115-31
pubmed: 25726562
Exp Hematol. 2012 Jun;40(6):466-76
pubmed: 22421183
Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):18066-71
pubmed: 23071320
Lancet. 2004 Sep 25-Oct 1;364(9440):1157-66
pubmed: 15451223
J Clin Med. 2021 Jun 02;10(11):
pubmed: 34199544
Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10214-9
pubmed: 10954737
Infect Agent Cancer. 2007 Jul 09;2:13
pubmed: 17620119
Am J Pathol. 2002 Oct;161(4):1127-33
pubmed: 12368186
PLoS One. 2016 Jan 05;11(1):e0145720
pubmed: 26731525
Clin Cancer Res. 2012 Feb 1;18(3):598-604
pubmed: 22065079
Clin Cancer Res. 2017 Jul 15;23(14):3929-3934
pubmed: 28174236
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S47-S59
pubmed: 32206570
Clinics (Sao Paulo). 2018 Oct 11;73(suppl 1):e558s
pubmed: 30328951
Mol Carcinog. 1999 Oct;26(2):93-9
pubmed: 10506753
J Med Virol. 2004 Dec;74(4):668-76
pubmed: 15484269
J Clin Endocrinol Metab. 2003 Feb;88(2):892-9
pubmed: 12574230
Oncol Lett. 2016 Mar;11(3):2051-2056
pubmed: 26998120
J Virol. 2003 May;77(9):5039-45
pubmed: 12692206
J Infect. 2020 May;80(5):563-570
pubmed: 32097686
Cancer Res. 2006 Nov 15;66(22):10786-94
pubmed: 17108115
Cancer Res. 1998 Oct 15;58(20):4505-9
pubmed: 9788590
CA Cancer J Clin. 2019 Sep;69(5):402-429
pubmed: 31283845
J Cell Physiol. 2012 Jan;227(1):44-58
pubmed: 21412769
Front Oncol. 2019 Jul 25;9:670
pubmed: 31403031
Am J Respir Cell Mol Biol. 2000 Dec;23(6):788-93
pubmed: 11104732
Cancer Res. 2005 Apr 15;65(8):3049-52
pubmed: 15833832
Hum Immunol. 2012 May;73(5):502-10
pubmed: 22387152
Int J Mol Sci. 2020 Jul 09;21(14):
pubmed: 32659970
Cancer Sci. 2006 Apr;97(4):292-5
pubmed: 16630121
Appl Immunohistochem Mol Morphol. 2020 Jul;28(6):444-447
pubmed: 31205069